柘中股份(002346.SZ)：由蘇信基金領投的首個投資項目皓元醫藥在科創板掛牌上市
格隆匯6月8日丨柘中股份(002346.SZ)公佈，蘇信基金首期募集資金為11.61億元，公司已完成全部認繳金額人民幣3億元的繳付，佔蘇信基金份額比例為25.84%。
蘇信基金設立以來，其投資領域主要集中在醫療健康及信息技術領域，投資目標為行業頭部企業，涵蓋CRO/CDMO、高端醫療影像、醫用內窺鏡、實驗室信息化與數據管理、信號鏈及模擬芯片設計、AI+教育、射頻前端、國家網絡空間安全、集成電路第三方測試等。
2021年6月8日，由蘇信基金領投的首個投資項目上海皓元醫藥股份有限公司(“皓元醫藥”)在上交所科創板公開掛牌上市，首日收盤價313.43元，收盤市值233億元，蘇信基金持股市值17.18億元。蘇信基金對皓元醫藥投資額為1.2億元人民幣，發行前持股數量為548.19萬股，持股比例9.83%，為皓元醫藥第二大股東；發行後持股數量為548.19萬股，持股比例7.37%，為皓元醫藥第二大股東。
截至公吿日，蘇信基金首期募集資金已基本投資完畢，重點投資醫療健康和信息技術兩大領域各細分行業龍頭公司，投資階段以成長期為主、早期為輔，區域集中在長三角、珠三角及北京等地，自成立以來已投資17個項目，除已上市的皓元醫藥外，無錫力芯微電子股份有限公司(蘇信基金投資2001萬元)已獲得發行批文；北京三維天地科技股份有限公司(蘇信基金投資5812萬元)已於2021年6月3日通過創業板發審會；上海澳華內鏡股份有限公司(蘇信基金投資2881萬元)科創板上市審核目前處於問詢階段；蘇州納芯微電子股份有限公司(蘇信基金投資500萬元)科創板上市申請於2021年5月28日獲上交所受理；年內預計還有5家已投公司計劃申報科創板或創業板上市；年內暫未有申報計劃的已投公司中，多家已在今年上半年完成新一輪融資。
此次皓元醫藥在上交所科創板上市後，預計會對公司業績產生正向影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
